Skip to main content
Fig. 6 | Molecular Cancer

Fig. 6

From: CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis

Fig. 6

CircEAF2 attenuates the progression of EBV + DLBCL in vivo. A In the untreated and epirubicin group, the growth curve of xenograft tumors transfected with circEAF2 overexpression and with vector. B Immunohistochemistry analysis of Ki-67 and TUNEL assay of cell apoptosis in xenograft tumors transfected with circEAF2 overexpression and with vector. HE, hematoxylin-eosin staining. Untreated, the untreated group; Epirubicin, the epirubicin group; Scale bar represents 200 μm. Data were shown as the mean ± S.D. of three experiments

Back to article page